These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30934066)

  • 1. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Fluge Ø; Rekeland IG; Lien K; Thürmer H; Borchgrevink PC; Schäfer C; Sørland K; Aßmus J; Ktoridou-Valen I; Herder I; Gotaas ME; Kvammen Ø; Baranowska KA; Bohnen LMLJ; Martinsen SS; Lonar AE; Solvang AH; Gya AES; Bruland O; Risa K; Alme K; Dahl O; Mella O
    Ann Intern Med; 2019 May; 170(9):585-593. PubMed ID: 30934066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
    Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
    PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
    Fluge Ø; Bruland O; Risa K; Storstein A; Kristoffersen EK; Sapkota D; Næss H; Dahl O; Nyland H; Mella O
    PLoS One; 2011; 6(10):e26358. PubMed ID: 22039471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
    Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
    PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.
    Rekeland IG; Fluge Ø; Alme K; Risa K; Sørland K; Mella O; de Vries A; Schjøtt J
    Clin Ther; 2019 May; 41(5):806-814. PubMed ID: 30502905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Rekeland IG; Sørland K; Neteland LL; Fosså A; Alme K; Risa K; Dahl O; Tronstad KJ; Mella O; Fluge Ø
    PLoS One; 2024; 19(7):e0307484. PubMed ID: 39042627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial.
    Skjevling L; Goll R; Hanssen HM; Johnsen PH
    BMJ Open; 2024 Jun; 14(6):e073275. PubMed ID: 38858151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.
    Rekeland IG; Fosså A; Lande A; Ktoridou-Valen I; Sørland K; Holsen M; Tronstad KJ; Risa K; Alme K; Viken MK; Lie BA; Dahl O; Mella O; Fluge Ø
    Front Med (Lausanne); 2020; 7():162. PubMed ID: 32411717
    [No Abstract]   [Full Text] [Related]  

  • 9. Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.
    Cash A; Kaufman DL
    J Transl Med; 2022 Jun; 20(1):295. PubMed ID: 35764955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
    Castro-Marrero J; Segundo MJ; Lacasa M; Martinez-Martinez A; Sentañes RS; Alegre-Martin J
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.
    Mensah F; Bansal A; Berkovitz S; Sharma A; Reddy V; Leandro MJ; Cambridge G
    Clin Exp Immunol; 2016 May; 184(2):237-47. PubMed ID: 26646713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.
    McKenzie R; O'Fallon A; Dale J; Demitrack M; Sharma G; Deloria M; Garcia-Borreguero D; Blackwelder W; Straus SE
    JAMA; 1998 Sep 23-30; 280(12):1061-6. PubMed ID: 9757853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.
    Naik H; Cooke E; Boulter T; Dyer R; Bone JN; Tsai M; Cristobal J; McKay RJ; Song X; Nacul L
    BMJ Open; 2024 May; 14(5):e085272. PubMed ID: 38740499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
    Strayer DR; Carter WA; Stouch BC; Stevens SR; Bateman L; Cimoch PJ; Lapp CW; Peterson DL; ; Mitchell WM
    PLoS One; 2012; 7(3):e31334. PubMed ID: 22431963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease.
    Sotzny F; Blanco J; Capelli E; Castro-Marrero J; Steiner S; Murovska M; Scheibenbogen C;
    Autoimmun Rev; 2018 Jun; 17(6):601-609. PubMed ID: 29635081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial.
    Sulheim D; Fagermoen E; Winger A; Andersen AM; Godang K; Müller F; Rowe PC; Saul JP; Skovlund E; Øie MG; Wyller VB
    JAMA Pediatr; 2014 Apr; 168(4):351-60. PubMed ID: 24493300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine.
    Joseph P; Pari R; Miller S; Warren A; Stovall MC; Squires J; Chang CJ; Xiao W; Waxman AB; Systrom DM
    Chest; 2022 Nov; 162(5):1116-1126. PubMed ID: 35526605
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.